Post—SABCS: update on targeted therapies in breast cancer
- 01.09.2025
- short review
Erschienen in:
- Verfasst von
- Lea Korber
- Kathrin Strasser-Weippl
- Erschienen in
- memo - Magazine of European Medical Oncology | Ausgabe 3/2025
Summary
Targeted therapies are indispensable in today’s cancer treatment and represent a constantly evolving field by creating more individual treatment strategies and reducing chemotherapy-associated toxicities. At the SABCS 2024 (San Antonio Breast Cancer Symposium), several studies were presented, offering exciting prospects for future therapeutic developments in the area of targeted therapies for breast cancer. Particularly noteworthy is the new maintenance therapy with palbociclib/endocrine therapy/trastuzumab/pertuzumab in HER2-positive metastatic breast cancer, which has already been included in clinical guidelines.
Anzeige
- Titel
- Post—SABCS: update on targeted therapies in breast cancer
- Verfasst von
-
Lea Korber
Kathrin Strasser-Weippl
- Publikationsdatum
- 01.09.2025
- Verlag
- Springer Vienna
- Erschienen in
-
memo - Magazine of European Medical Oncology / Ausgabe 3/2025
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076 - DOI
- https://doi.org/10.1007/s12254-025-01056-1
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.